Abstract 1730P
Background
We hypothesized that PARP inhibitor Fluzoparib and preoperative radiotherapy (RT) will transform inoperable or borderline operable soft tissue sarcoma (STS) into an operable disease without increase of major wound complications (MWCs).
Methods
Primary or recurrent non-metastatic unresectable or borderline resectable extremity or trunk STS was enrolled. Patients received preoperative moderately fractionated RT of 43.5Gy in 15 fractions with concurrent and sequential Fluzoparib (100mg Bid for 10 weeks in total), followed by wide resection. NCI-CTC 5.0, RECIST 1.1 criteria, and EORTC-STBSG criteria was used to evaluate acute toxicities, clinical and pathological response. The primary endpoint was defined as MWCs as per the SR2 criteria within 4 months post-surgery.
Results
From Jun 2023 to Apr 2024, 49 patients were enrolled and 46 completed RT. Forty-six tumours (93.9%) were evaluated as unresectable or borderline resectable, with 40 tumor (81.6%) adjacent to or encircling key structures. There were 40, 6 and 3 patients having full-dose Fluzoparib, drug dose reduction and RT alone, respectively. The observed ≥Grade 3 Fluzoparib-related or RT-related acute toxicity is anemia in 1 patient, and skin reaction in two patients. There're 8 (8/43, 18.6%), 11 (25.6%) and 24 patients (55.8%) who achieved PR, tumor reduction by 20% and SD as per RECIST 1.1 at 4-6 weeks post-radiotherapy, respectively. Till May, 2024, there were 40 patients who underwent non-R2 limb-conserving surgery, with 26 R0 and 14 R1 resection (margin less than 1mm). Thirteen out of 37 patients (35.1%) with at least 6 weeks follow-up had MWCs, with 12 in lower extremity (12/33, 36.4%). As per the EORTC criteria, there were 1 (1/38, 2.6%), 7 (18.4%) and 10 (26.3%) patients achieving pathological Grade B, C, and D remission. In all, 28 patients (73.7%) had higher than 10% of hyalinization/fibrosis.
Conclusions
For patients with non-metastatic extremity or trunk STS, the combination of PARP inhibitor and pre-operative moderately fractionated RT is safe and well-tolerated, and make majority of tumors transformed into operable disease.
Clinical trial identification
NCT05938374.
Editorial acknowledgement
Funding
CAMS Innovation Fund for Medical Sciences (CIFMS) [grant number 2023-I2M-C&T-B-089] and the Beijing Hope Run Special Fund of Cancer Foundation of China [grant number LC2020A15].
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1752P - A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma
Presenter: Olayode Babatunde
Session: Poster session 06
1753P - Outcomes of multidisciplinary treatment of localized myxofibrosarcoma: Retrospective analysis from a reference center
Presenter: Iwona Kalinowska
Session: Poster session 06
1755P - Multimodal therapy in first line treatment of very high risk Ewing sarcoma patients: Results of the French prospective multicenter COMBINAIR3 phase II trial
Presenter: Valerie Laurence
Session: Poster session 06
1756P - A phase I/II trial of gemcitabine, docetaxel, and hydroxychloroquine in advanced/metastatic osteosarcoma
Presenter: J Andrew Livingston
Session: Poster session 06
1757P - Proceedings of the think tank for osteosarcoma medical advisory board meeting
Presenter: Sant Chawla
Session: Poster session 06
1758P - Real-world efficacy of imatinib in patients with advanced GIST: The LRG registry
Presenter: Gahyun Gim
Session: Poster session 06
1759P - Long-term updated outcomes of a phase II study of ripretinib vs. sunitinib in chinese patients with advanced gastrointestinal stromal tumor
Presenter: Jian Li
Session: Poster session 06
1760P - Impact of adjuvant imatinib on recurrence for neurofibromatosis type 1 (NF1) associated GISTs: An analysis of the RECKGIST cohort from the French NETSARC+ network
Presenter: Vincent Hautefeuille
Session: Poster session 06
1761P - Clinical description and development of a prognosis score for neurofibromatosis type 1 (NF1) associated GISTs in the RECKGIST cohort: A retrospective study from the French NETSARC+ network
Presenter: Charlotte Cuvelier
Session: Poster session 06